[1] |
SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2018[J]. CA A Cancer J Clin, 2018, 68(1): 7-30.
doi: 10.3322/caac.21442
|
[2] |
RAMESH H. Management of pancreatic cancer: current status and future directions[J]. Indian J Surg, 2010, 72(4): 285-289.
doi: 10.1007/s12262-010-0123-3
pmid: 21938189
|
[3] |
REYNGOLD M, O’REILLY E M, VARGHESE A M, et al. Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer[J]. JAMA Oncol, 2021, 7(5): 735-738.
doi: 10.1001/jamaoncol.2021.0057
pmid: 33704353
|
[4] |
REYNGOLD M, PARIKH P, CRANE C H. Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results[J]. Radiat Oncol, 2019, 14(1): 95.
doi: 10.1186/s13014-019-1309-x
pmid: 31171025
|
[5] |
MARKS L B, YORKE E D, JACKSON A, et al. Use of normal tissue complication probability models in the clinic[J]. Int J Radiat Oncol Biol Phys, 2010, 76(3 Suppl): S10-S19.
doi: 10.1016/j.ijrobp.2009.07.1754
|
[6] |
HODAPP N. The ICRU Report 83: prescribing, recording and reporting photon-beam intensity-modulated radiation therapy (IMRT)[J]. Al, 2012, 188(1): 97-99.
|
[7] |
IACOBUZIO-DONAHUE C A, FU B J, YACHIDA S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer[J]. J Clin Oncol, 2009, 27(11): 1806-1813.
doi: 10.1200/JCO.2008.17.7188
|
[8] |
CRANE C H, VARADHACHARY G R, YORDY J S, et al. Phase Ⅱ trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4 (Dpc4) immunostaining with pattern of disease progression[J]. J Clin Oncol, 2011, 29(22): 3037-3043.
doi: 10.1200/JCO.2010.33.8038
|
[9] |
GUTT R, LIAUW S L, WEICHSELBAUM R R. The role of radiotherapy in locally advanced pancreatic carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2010, 7(8): 437-447.
doi: 10.1038/nrgastro.2010.98
pmid: 20628346
|
[10] |
RUDRA S, JIANG N M, ROSENBERG S A, et al. Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer[J]. Cancer Med, 2019, 8(5): 2123-2132.
doi: 10.1002/cam4.2100
|
[11] |
KRISHNAN S, CHADHA A S, SUH Y, et al. Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation[J]. Int J Radiat Oncol Biol Phys, 2016, 94(4): 755-765.
doi: 10.1016/j.ijrobp.2015.12.003
|
[12] |
SMYTH G, EVANS P M, BAMBER J C, et al. Recent developments in non-coplanar radiotherapy[J]. Br J Radiol, 2019, 92(1097): 20180908.
doi: 10.1259/bjr.20180908
|
[13] |
STEFANOWICZ S, STÜTZER K, ZSCHAECK S, et al. Comparison of different treatment planning approaches for intensity-modulated proton therapy with simultaneous integrated boost for pancreatic cancer[J]. Radiat Oncol, 2018, 13(1): 228.
doi: 10.1186/s13014-018-1165-0
pmid: 30466468
|
[14] |
DONG P, LEE P, RUAN D, et al. 4π non-coplanar liver SBRT: a novel delivery technique[J]. Int J Radiat Oncol Biol Phys, 2013, 85(5): 1360-1366.
doi: 10.1016/j.ijrobp.2012.09.028
|
[15] |
SOYFER V, CORN B W, MELAMUD A, et al. Three-dimensional non-coplanar conformal radiotherapy yields better results than traditional beam arrangements for adjuvant treatment of gastric cancer[J]. Int J Radiat Oncol Biol Phys, 2007, 69(2): 364-369.
doi: 10.1016/j.ijrobp.2007.03.032
|
[16] |
CHU J C, SOLIN L J, HWANG C C, et al. Three-dimensional dosimetric comparison of radiation therapy treatment planning of the pancreas[J]. Med Dosim, 1992, 17(4): 199-203.
pmid: 1485907
|
[17] |
DIAZ L, UREFIA A, CASTRO I, et al. 2062 POSTER comparative study between coplanar and non-coplanar techniques in radiotherapy of abdominal tumours[J]. Eur J Cancer, 2011, 47: S206-S207.
|